QTRX Stock Forecast: Quanterix Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Quanterix Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Momentum (16): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
QTRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on QTRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | TD Cowen | Maintains | Hold | $3.50 → $4.00 |
| 13 Oct 2026 | TD Cowen | Maintains | Hold | $3.00 → $3.50 |
| 17 Aug 2026 | Canaccord Genuity | Maintains | Hold | $4.00 → $3.00 |
| 11 Aug 2026 | TD Cowen | Maintains | Hold | $4.00 → $3.00 |
| 7 May 2026 | TD Cowen | Maintains | Hold | $7.00 → $4.00 |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Hold | — |
| 22 Dec 2025 | Canaccord Genuity | Maintains | Hold | — |
| 11 Aug 2025 | Canaccord Genuity | Downgrade | Hold | — |
| 13 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 30 Apr 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 25 Mar 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 18 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 13 Nov 2024 | TD Cowen | Maintains | Hold | — |
| 12 Aug 2024 | Scotiabank | Maintains | Sector Outperform | — |
| 9 Aug 2024 | TD Cowen | Maintains | Hold | — |
| 9 July 2024 | Goldman Sachs | Maintains | Buy | — |
| 29 Apr 2024 | Canaccord Genuity | Maintains | Buy | — |
| 4 Mar 2024 | Scotiabank | Maintains | Sector Outperform | — |
| 28 Sept 2023 | Goldman Sachs | Maintains | Buy | — |
| 27 Sept 2023 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
QTRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
QTRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Quanterix Corp. returned −66.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
QTRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.6×
- Price / book
- 0.4×
- EV / EBITDA
- —
Cheaper than 76% of US stocks
Cheaper than 88% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 38.5%
- Operating margin
- −53.6%
- Net margin
- —
Higher than 47% of US stocks
Higher than 18% of US stocks
- Return on equity
- −41.7%
- Return on assets
- −13.3%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Quanterix Corp. has a market value of $96.4M and an enterprise value of $50.4M.
Revenue in the twelve months to 30 June 2026: $153.2M. The latest quarter grew 34.6% year on year.
Net income over the same four quarters: −$123.1M, a −80.3% net margin.
Diluted earnings per share, trailing twelve months: −$2.63.
Free cash flow in the twelve months to 30 June 2026: −$81.7M.
Quanterix Corp. employs 450 people — $341K of revenue per employee.
Data provided by Twelve Data
QTRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at QTRX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Quanterix Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about QTRX
How does Ticker Nerd's model rank QTRX?
As at 21 Nov 2026, Quanterix Corp. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
What is the QTRX stock forecast for 2030?
No analyst covering Quanterix Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.
How has QTRX stock performed over the past year?
Quanterix Corp. returned -66.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Quanterix Corp. do?
Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids.
About Quanterix Corp.
Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids. The company supports work across disease research, diagnostics, and drug development, helping laboratories and healthcare organizations generate precise biomarker data for scientific and clinical use. Quanterix serves customers in North America, Europe, the Middle East, Africa, and the Asia Pacific regions, with offerings used by academic researchers, biopharmaceutical companies, and clinical laboratories. Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix Corporation plays a specialized role in precision biomarker science and advanced diagnostic testing.
CEO Mr. Everett V. Cunningham · 450 employees · United States · https://www.quanterix.com